Triptonide suppresses the FOXK1/AKT2 axis to reverse malignant phenotype and improve cisplatin efficacy in esophageal squamous cell carcinoma
The FOXK1/AKT2 signaling axis contributes to cisplatin resistance in ESCC. Triptonide reverses resistance by inhibiting this axis, offering a promising strategy to enhance cisplatin efficacy in ESCC therapy.
Authors
- X. Li (ORCID: https://orcid.org/0009-0000-7914-2762)
- Tongxin Xu (ORCID: https://orcid.org/0000-0002-5418-3020)
- Liying Chen (ORCID: https://orcid.org/0000-0003-0990-7648)
- Yan Zhao (ORCID: https://orcid.org/0000-0002-7760-916X)
- Zhaoyang Yan
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Hebei University of Chinese Medicine (CN)
Publication Details
- Journal
- Genes & Genomics
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1007/s13258-025-01701-3
- Primary Topic
- Natural Compounds in Disease Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00